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http://www.biomedcentral.com/1471-2407/12/321RESEARCH ARTICLE Open AccessOverexpression of cell cycle regulator CDCA3
promotes oral cancer progression by enhancing
cell proliferation with prevention of G1
phase arrest
Fumihiko Uchida1, Katsuhiro Uzawa2,3*, Atsushi Kasamatsu3, Hiroaki Takatori4, Yosuke Sakamoto3,
Katsunori Ogawara3, Masashi Shiiba3, Hideki Tanzawa2,3 and Hiroki Bukawa1,5Abstract
Background: Cell division cycle associated 3 (CDCA3), part of the Skp1-cullin-F-box (SCF) ubiquitin ligase, refers
to a trigger of mitotic entry and mediates destruction of the mitosis inhibitory kinase. Little is known about the
relevance of CDCA3 to human malignancy including oral squamous cell carcinoma (OSCC). We aimed to
characterize the expression state and function of CDCA3 in OSCC.
Methods: We evaluated CDCA3 mRNA and protein expression in both OSCC-derived cell lines and primary OSCCs
and performed functional analyses of CDCA3 in OSCC-derived cells using the shRNA system.
Results: The CDCA3 expression at both the mRNA and protein levels was frequently up-regulated in all cell lines
examined and primary tumors (mRNA, 51/69, 74 %; protein, 79/95, 83 %) compared to normal controls (p< 0.001).
In contrast, no significant level of CDCA3 protein expression was seen in oral premalignant lesions (OPLs) (n= 20)
compared with the expression in OSCCs. Among the clinical variables analyzed, the CDCA3 expression status was
closely related to tumor size (p< 0.05). In addition, suppression of CDCA3 expression with shRNA significantly
(p< 0.05) inhibited cellular proliferation compared with the control cells by arresting cell-cycle progression at the
G1 phase. Further, there was up-regulation of the cyclin-dependent kinase inhibitors (p21Cip1, p27Kip1, p15INK4B,
and p16INK4A) in the knockdown cells.
Conclusion: The current results showed that overexpression of CDCA3 occurs frequently during oral carcinogenesis
and this overexpression might be associated closely with progression of OSCCs by preventing the arrest of
cell-cycle progression at the G1 phase via decreased expression of the cyclin-dependent kinase inhibitors.
Keywords: Cell division cycle associated 3, Oral squamous cell carcinoma, Proliferation, Cell-cycle arrest,
Cyclin-dependent kinase inhibitorsBackground
Rapid cellular growth and division are common features
in all malignant cells including oral squamous carcinoma
[1]. It is well documented that inappropriate expres-
sion of cell-cycle regulatory proteins can contribute
to human tumorigenesis [2]. Numerous studies have* Correspondence: uzawak@faculty.chiba-u.jp
2Department of Clinical Molecular Biology, Graduate School of Medicine,
Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
3Division of Dentistry and Oral-Maxillofacial Surgery, Chiba University
Hospital, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
Full list of author information is available at the end of the article
© 2012 Uchida et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orreported the relation between carcinogenesis and the
cell-cycle-related gene [3-6]. In particular, recent studies
have suggested that deregulation of Skp1-cullin-F-box
(SCF) control of the G1/S phase targets also might con-
tribute to human tumorigenesis [3,7-9].
Our previous microarray analysis showed that CDCA3,
referred to as a trigger of mitotic entry, mediates
destruction of mitosis and the inhibitory kinase via the
E3 ligase, SCF [10-14] and was one of the up-regulated
genes in the oral squamous cell carcinoma (OSCC)-
derived cells [15]. The ubiquitin-proteasome system isLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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over and thus maintains cellular protein homeostasis
[16]. Although protein ubiquitination is catalyzed by a
highly ordered enzymatic cascade, including ubiquitin-
activating enzyme E1s, ubiquitin-conjugating enzyme
E2s, and ubiquitin ligase E3s, the last of which primarily
determine the substrate specificity [16,17]. The SCF,
E3 ubiquitin ligases, consisting of Skp1, cullins/cdc53,
F-box proteins, and the RING domain containing protein
regulator of cullins-1 (ROC1)/ring box protein-1, are
crucial to the regulation of numerous cellular processes
under both physiologic and pathologic conditions as part
of the ubiquitin-proteosome system [18]. By promoting
degradation of many short-lived proteins, including cell
cycle regulators, transcription factors and signal transdu-
cers, SCF E3 ligases regulate many biological processes
[19]. CDCA3 is a protein that contains an F box motif
and bind to Skp1 and cullin, a component of SCF. Since
the F-box protein determines the specificity of SCF
ligases, it represents a target that could provide the
greatest potential selectivity [20]. As a critical cell-cycle
regulator, p27 Kip1 arrests cell division and inhibits G1/S
transition, and the cellular p27Kip1 levels are modulated
largely through the ubiquitin-proteasome pathway [21].
Thus, progression of the cell cycle can be regulated by
modulating the quantities of cell-cycle regulators
through ubiquitination by the SCF complex [1]. How-
ever, the expression state and function of CDCA3 in
OSCCs are not fully characterized.
The current study shows the results of a compre-
hensive analysis of aberrant expression of CDCA3 in
OSCCs that are clinically and functionally linked to
tumor progression.
Methods
Cell culture
HSC-2, HSC-3, HSC-4, and Ca9-22 cell lines, derived
from human OSCCs, were purchased from the Human
Science Research Resources Bank, Osaka, Japan. H1 and
Sa3 were kindly provided by Dr. S. Fujita of Wakayama
Medical University, Wakayama, Japan. HNOKs were
used as a normal control [22,23]. All cells were grown in
Dulbecco’s modified Eagle medium (DMEM) F-12 HAM
(Sigma Aldrich, St. Louis, MO) supplemented with 10%
fetal bovine serum (FBS) (Sigma) and 50 units/ml peni-
cillin and streptomycin (Sigma).
Tissue specimens
Primary OSCC samples and corresponding normal oral
epithelial tissues were obtained at the time of surgeries
performed at Chiba University Hospital. All patients
provided informed consent for the study protocol, which
was approved by the institutional review board of Chiba
University. The tissues were divided into two parts, oneof which was frozen immediately and stored at −80°C
until RNA isolation, and the second was fixed in 20%
buffered formaldehyde solution for pathologic diag-
nosis and IHC. The Department of Pathology, Chiba
University Hospital, performed the histopathologic diag-
nosis of each tissue according to the World Health
Organization criteria. Clinicopathological staging was
determined according to the tumor-node-metastases
classification of the International Union against Cancer.
All OSCC samples were confirmed histologically and
checked to ensure the presence of tumor in greater than
90% of specimens.
Preparation of cDNA
Total RNA was isolated using Trizol Reagent (Invitro-
gen, Carlsbad, CA) according to the manufacturer’s
instructions. cDNA was generated from 5 μg of total
RNA using Ready-To-Go You-Prime First-Strand Beads
(GE Healthcare, Buckinghamshire, UK) and oligo (dT)
primer (Sigma Genosys, Ishikari, Japan), according to
the manufacturer’s instructions.
mRNA expression analysis
qRT-PCR was performed to evaluate the expression
levels of CDCA3 and Wee1 mRNA in OSCC-derived cell
lines and HNOKs. We also evaluated the mRNA levels
in primary OSCCs and paired specimens of normal oral
tissues obtained from 69 patients. qRT-PCR was per-
formed using LightCycler 480 apparatus (Roche Diag-
nostics GmbH, Mannheim, Germany). Primers were
designed using the ProbeFinder qPCR assay design soft-
ware, which is freely accessible at www.universalprobeli-
brary.com. The sequences of the gene-specific primers
were as follows: CDCA3 forward 5’-TGGTATTGCAC
GGACACCTA-3’ and reverse 5’-TGTTTCACCAGTG
GGCTTG-3’; Wee1 forward 5’-TTTGGTTCACATGG
ATATAAAACCT-3’ and reverse 5’-CCCAATCATCTT
CGTCTCCT-3’. The PCR reactions were carried out in
a final volume of 20 μl of a reaction mixture comprised
of 10 μl of LightCycler 480 Probes Master (Roche),
0.2 μl of universal probe (Roche), and 4 μM of the pri-
mers, according to the manufacturer’s instructions. The
reaction mixture was loaded onto the PCR plate and
subjected to an initial denaturation at 95°C for 10 min,
followed by 45 rounds of amplification at 95°C (10 sec)
for denaturation, 60°C (30 sec) for annealing, and 72°C
(1 sec) for extension, followed by a cooling step at 50°C
for 30 seconds. The transcript amounts for the CDCA3
and Wee1 genes were estimated from the respective
standard curves and normalized to the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) forward 5’-AGCC
ACATCGCTCAGACAC-3’ and reverse 5’-GCCCAA
TACGACCAAATCC-3’ transcript amount determined
in corresponding samples.
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The cells were washed twice with cold phosphate buf-
fered saline (PBS) and centrifuged briefly. The cell pel-
lets were incubated at 4°C for 30 min in a lysis buffer
(7 M urea, 2 M thiourea, 4%w/v CHAPS, and 10 mM
Tris pH 7.4) with a proteinase inhibitor cocktail (Roche).
The protein concentration was measured using the
Bradford reagent (Bio-Rad, Richmond, CA). Protein
extracts were electrophoresed on 4% to 12% Bis-Tris gel,
transferred to nitrocellulose membranes (Invitrogen),
and blocked for 1 hr at room temperature with Blocking
One (Nacalai Tesque, Inc., Kyoto, Japan). The mem-
branes were washed three times with 0.1 % Tween-20 in
Tris-buffered saline and incubated with antibody for
CDCA3 (Abcam, Cambridge, UK), p21Cip1, p27Kip1,
p15INK4B, p16INK4A, CDK4, CDK6, Cyclin D1 (Cell Sig-
naling Technology, Danvers, MA), and Cyclin E (Santa
Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C
and α-tubulin (Santa Cruz Biotechnology) 1 hr at room
temperature. The membranes were washed again and
incubated with a anti-rabbit or anti-mouse IgG (H+L)
horseradish peroxidase conjugate (Promega, Madison,
WI) as a secondary antibody for 1 hr at room temperature.
Finally, the membranes were detected using Super-
Signal West Pico Chemiluminescent substrate (Thermo,
Rockford, IL), and immunoblotting was visualized by ex-
posing the membranes to ATTO Light-Capture II (Tokyo,
Japan). Signal intensities were quantitated using the CS
Analyzer version 3.0 software (ATTO).
IHC
IHC of 4-μm sections of paraffin-embedded specimens
was performed using rabbit anti-CDCA3 polyclonal anti-
body (Abcam). Briefly, after deparaffinization and hydra-
tion, the endogeneous peroxidase activity was quenched
by a 30 min incubation in a mixture of 0.3% hydrogen
peroxide solution in 100% methanol, after which the sec-
tions were blocked for 2 hr at room temperature with
1.5% blocking serum (Santa Cruz Biotechnology) in PBS
before reaction overnight with anti-CDCA3 antibody
(1:100 dilution) at 4°C in a moist chamber. Upon incu-
bation with the primary antibody, the specimens were
washed three times in PBS and treated with Envision re-
agent (DAKO, Carpinteria, CA) followed by color devel-
opment in 3,3’-diaminobenzidine tetrahydrochloride
(DAKO). The slides then were lightly counterstained
with hematoxylin, dehydrated with ethanol, cleaned
with xylene, and mounted. Non-specific binding of an
antibody to proteins other than the antigen sometimes
occurred. To avoid non-specific binding, an immuniz-
ing peptide blocking experiment was performed. As
a negative control, triplicate sections were immunos-
tained without exposure to primary antibodies, whichconfirmed the staining specificity. To quantify the status
of the CDCA3 protein expression in those components,
we used an IHC scoring system described previously
[22-26]. This IHC scoring system was established for
quantitative evaluation of IHC staining. The stained cells
were determined in at least five random fields at
400 ×magnification in each section. We counted 300
cells per one field of vision. The staining intensity
(1, weak; 2, moderate; 3, intense) and the number of
positive cells in the field of vision then were multiplied
to calculate the IHC score using the following formula:
IHC score = 1 × (number of weakly stained cells in the
field) + 2 × (number of moderately stained cells in the
field) + 3 × (number of intensely stained cells in the field).
Cases with a CDCA3 IHC score exceeding 94.7 (max-
imum score within + 3 standard deviation (SD) of the
mean of normal tissues) were defined as CDCA3-
positive because 100% of the distribution falls within ± 3
SD of the mean in normal tissues. Two independent
pathologists, both masked to the patients’ clinical status,
made these judgments.
Stable transfection of CDCA3 shRNA
Stable transfection was performed at about 80% con-
fluency in 24 well plates using Lipofectamine LTX and
Plus Reagents (Invitrogen), according to the manufac-
turer’s instructions. Briefly, a total of 2 × 105 cells were
seeded into each well in DMEM F-12 HAM (Sigma)
containing 10% FBS (Sigma) without antibiotics.
shCDCA3 and mock (0.1 μg) (Santa Cruz Biotechnol-
ogy) vectors were transfected into OSCC-derived cells
(H1 and Sa3) with 0.5 μl of Plus Reagents and 1.25 μl of
Lipofectamine LTX. After transfection, the cells were
isolated by the culture medium containing 2 μg/mL
puromycin (Invitrogen). After 3 to 4 weeks, resistant cell
clones were picked and transferred to 6-well plates and
gradually expanded to 10-cm dishes. At 90% confluence,
qRT-PCR and Western blot analyses were performed to
assess the efficiency of CDCA3 knockdown.
Cellular growth
To evaluate the effect of CDCA3 knockdown on cellular
proliferation, we analyzed cellular growth in shCDCA3-
and mock-transfected cells. These transfectants were
seeded in 6-well plates at a density of 1 × 104 viable cells
per well. The experiments were carried out for 168 hr,
and the cells were counted every 24 hr. At the indicated
time point, the cells were trypsinized and counted using
a hemocytometer in triplicate samples.
Cell-cycle analysis
To assess cell-cycle distribution of entire cell popu-
lations, the cells were harvested, washed with PBS,
and probed with CycleTEST Plus DNA reagent kit
Figure 1 Evaluation of CDCA3 expression in OSCC-derived cell
lines. A) Quantification of CDCA3 mRNA expression in OSCC-derived
cell lines by qRT-PCR analysis. Significant up-regulation of CDCA3
mRNA is seen in six OSCC-derived cell lines compared with the
HNOKs (*p< 0.05, Mann-Whitney’s U test). Data are expressed as the
means ± SEM of triplicate results. B) A representative Western blot of
CDCA3 protein in OSCC-derived cell lines and HNOKs shows that
CDCA3 protein expression is up-regulated in OSCC-derived cell lines
compared with HNOKs. Densitometric CDCA3 protein data are
normalized to α-tubulin protein levels. The values are expressed as
a percentage of the HNOKs.
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ufacturer’s protocol. Briefly, the cells were centrifuged at
400 × g for 5 min. The cell pellets were resuspended with
250 μl of trypsin buffer, and incubated for 10 min
at room temperature. We then added 200 μl of trypsin
inhibitor and RNase buffer. Finally, the cells were labeled
with 200 μl of propidium iodide stain solution. Flow
cytometric determination of DNA content was analyzed
by FACSCalibur (Becton-Dickinson). The fractions of
the cells in the G0-G1, S, and G2-M phases were ana-
lyzed using Flow Jo software (Tree Star, Ashland, OR).
Statistical analysis
Statistical significance was determined using Fisher’s
exact test or the Mann-Whitney’s U test. p< 0.05 was
considered significant. The data are expressed as the
mean ± standard error of the mean (SEM).
Results
Evaluation of CDCA3 expression in OSCC-derived cell
lines and primary OSCCs
To investigate mRNA and protein expression of CDCA3
identified as a cancer-related gene in our previous
microarray data [15], we performed real-time quantita-
tive reverse transcriptase-polymerase chain reaction
(qRT-PCR) and Western blot analyses using six OSCC-
derived cell lines (HSC-2, HSC-3, HSC-4, Ca9-22,
H1, and Sa3) and primary cultured human normal oral
keratinocytes (HNOKs). CDCA3 mRNA was signifi-
cantly (*p< 0.05) up-regulated in all OSCC-derived cell
lines compared with the HNOKs (Figure 1A). Figure 1B
shows representative results of Western blot analysis.
The molecular weight of CDCA3 was 29 kDa. A signifi-
cant increase in CDCA3 protein expression was seen in
all OSCC-derived cell lines compared with the HNOKs.
Expression analysis indicated that both transcription
and translation products of this molecule were highly
expressed in OSCC-derived cell lines. We then mea-
sured the CDCA3 mRNA expression levels in primary
OSCCs and paired normal oral tissues from 69 patients
(Figure 2A). Similar to the data from the OSCC-derived
cell lines, qRT-PCR analysis showed that CDCA3 mRNA
expression was up-regulated in 51 (74%) of 69 primary
OSCCs compared with the matched normal oral tissues.
The relative mRNA expression levels in the normal oral
tissues and primary OSCCs ranged from 6.3 × 10-5 to
0.442 (median, 0.033) and 5.9 × 10-5 to 1.178 (median,
0.083), respectively. When we analyzed the CDCA3 pro-
tein expression in primary OSCCs and paired normal
oral tissues from 95 patients and oral premalignant
lesions (OPLs) from 20 patients using the immunohisto-
chemistry (IHC) scoring system, the CDCA3 IHC scores
in the primary OSCCs, OPLs, and normal oral tissues
ranged from 2.5 to 225.0 (median, 95.0), 2.5 to 50.0(median, 15.0), and 2.5 to 87.5 (median, 22.5), respect-
ively. The CDCA3 IHC score in primary OSCCs was sig-
nificantly (**p< 0.001) higher than those in OPLs and
normal oral tissues (Figure 2B); there was no significant
difference in the IHC scores between the OPLs and nor-
mal oral tissues. Representative IHC results for CDCA3
protein in normal oral tissues, OPLs, and primary
OSCCs are shown in Figure 2C, D, and E. Strong
CDCA3 immunoreactions were detected in the cyto-
plasm in the OSCCs; the OPLs and normal oral tissues
showed negative immunostaining. CDCA3 protein expres-
sion was up-regulated in 79 (83%) of 95 primary OSCCs
Figure 2 Evaluation of CDCA3 expression in normal oral tissues, OPLs, and primary OSCCs. A) qRT-PCR analysis shows that CDCA3
mRNA expression is up-regulated in 51 (74 %) of 69 primary OSCCs compared with the matched normal oral tissues. The relative mRNA
expression levels in the normal oral tissues and primary OSCCs range from 6.3 × 10-5 to 0.442 (median, 0.033) and 5.9 × 10-5 to 1.178 (median,
0.083), respectively. Significantly higher CDCA3 mRNA expression is seen in primary OSCCs than matched normal oral tissues (**p< 0.001,
Mann-Whitney’s U test). B) The status of CDCA3 protein expression in primary OSCCs and paired normal oral tissues from 95 patients and OPLs
from 20 patients based on an IHC scoring system. The CDCA3 IHC scores of normal oral tissues, OPLs, and OSCCs range from 2.5 to 87.5 (median,
22.5), 2.5 to 50.0 (median, 15.0), and 2.5 to 225.0 (median, 95.0), respectively. The CDCA3 protein expression level in OSCCs is significantly higher
(**p< 0.001, Mann-Whitney’s U test) than in normal oral tissues and OPLs. No significant (p=not significant [n.s.]) difference in protein expression
is seen between OPLs and normal oral tissues. Representative IHC results of CDCA3 in normal oral tissues (C), OPLs (D) and primary OSCCs (E)
(×100 magnification. Scale bars, 50 μm.). A strong CDCA3 immunoreaction is seen in OSCCs, whereas normal oral tissues and OPLs show almost
negative immunostaining.
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relations between the clinicopathologic characteristics of
the patients with OSCC and the status of the CDCA3 pro-
tein expression using the IHC scoring system are shown
in Table 1. Among the clinical classifications, CDCA3-
positive OSCCs were correlated significantly (*p< 0.05)
with tumor size.
Establishment of CDCA3 knockdown cells
OSCC-derived cells (H1 and Sa3) transfected with CDCA3
shRNA (shCDCA3) and the control shRNA (mock) plas-
mid were cloned. qRT-PCR and Western blot anal-
yses were performed to assess the efficiency of CDCA3
knockdown. CDCA3 mRNA expression in shCDCA3-
transfected cells was significantly (*p< 0.05) lower than in
mock-transfected cells (Additional file 1A and B). CDCA3
protein levels in shCDCA3-transfected H1 (Figure 3A)
and Sa3 (Figure 3B) cells also decreased markedly com-
pared with mock-transfected cells. The densitometric
CDCA3 protein levels in shCDCA3-transfected cells
decreased significantly (*p< 0.05) compared with the
levels in the mock-transfected cells (Additional file 1C and
D). The CDCA3 protein expression levels were consistent
with the mRNA levels in the transfectants.Reduced cellular growth in CDCA3 knockdown cells
To investigate the antiproliferative effects in shCDCA3-
transfected cells, cellular growth was monitored for 168 hr.
The shCDCA3-transfected H1 (Figure 3A) and Sa3
(Figure 3B) cells showed a significant decrease in cellular
growth compared with mock-transfected cells (*p< 0.05).
Knockdown of CDCA3 promotes cell-cycle arrest with
cell-cycle regulators
To investigate the mechanism by which down-regulated
CDCA3 is related to cell-cycle progression, we per-
formed fluorescence-activated cell sorting (FACS) ana-
lysis of shCDCA3-transfected cells. A representative
FACS analysis of shCDCA3- and mock-transfected
cells is shown in Figure 4A. The percentage of the
G1 phase in shCDCA3-transfected cells was significantly
(*p< 0.05) higher than in mock-transfected cells. To
identify the mechanism by which down-regulated
CDCA3 blocks G1 progression, we assessed the protein
expression level of cyclin-dependent kinase inhibitors
(CDKIs) (p21Cip1, p27Kip1, p15 INK4B, p16INK4A), CDK4,
CDK6, Cyclin D1, and Cyclin E (Figure 4B, Addi-
tional file 2A, and B). The protein expression data
showed up-regulation of p21Cip1, p27Kip1, p15INK4B,
Table 1 Correlation between CDCA3 expression and
clinical classification in OSCCs
Results of immunostaining
Clinical classification No. patients (%)
Total CDCA3
negative
CDCA3
positive
p value
Age at surgery (years)
<60 23 9 (39) 14 (61)
≧60, <70 22 11 (50) 11 (50) 0.852
≧70 50 22 (44) 28 (56)
Gender
Male 58 28 (48) 30 (52) 0.317
Female 37 14 (38) 23 (62)
T-primary tumor
T1 6 3 (50) 3 (50) 0.020*
T2 56 30 (54) 26 (46)
T3 15 5 (33) 10 (67)
T4 18 4 (22) 14 (78)
T1 + T2 62 33 (53) 29 (47) 0.015*
T3 + T4 33 9 (27) 24 (73)
N-regional lymph node
N (−) 56 25 (45) 31 (55) 0.919
N (+) 39 17 (44) 22 (56)
Stage
I 6 3 (50) 3 (50) 0.235
II 36 18 (50) 18 (50)
III 17 8 (47) 9 (53)
IV 36 13 (36) 23 (64)
Histopathologic type
Well 60 26 (43) 34 (57) 0.803
Moderately 31 14 (45) 17 (55)
Poorly 4 2 (50) 2 (50)
Tumor site
Gingiva 28 9 (32) 19 (68) 0.456
Tongue 51 25 (49) 26 (51)
Buccal mucosa 9 4 (44) 5 (56)
Oral floor 7 4 (57) 3 (43)
*p< 0.05.
Figure 3 Proliferation of shCDCA3-transfected H1 (A) and
Sa3 (B) cells. The shCDCA3-transfected H1 and Sa3 cells show a
significant (*p< 0.05, Mann-Whitney’s U test) decrease in cellular
growth compared with mock-transfected cells. The results are
expressed as the means ± SEM of values from three assays.
Representative Western blot data shows that CDCA3 proteins are
markedly down-regulated in shCDCA3-transfected H1 (A) and
Sa3 (B) cells.
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CDK6 and Cyclin E in the CDCA3 knockdown cells. In
addition, to investigate mRNA expression ofWee1, a down-
stream molecule of CDCA3, we performed qRT-PCR ana-
lysis using six OSCC-derived cell lines (HSC-2, HSC-3,
HSC-4, Ca9-22, H1, and Sa3) and HNOKs. Wee1 mRNA
was significantly (*p< 0.05) down-regulated in all OSCC-
derived cell lines compared with the HNOKs (Additional
file 3). We also measured Wee1 expression in CDCA3knockdown cells. The qRT-PCR data showed that down-
regulation of CDCA3 induced a significant (*p< 0.05) in-
crease of Wee1 mRNA levels compared with mock-
transfected cells (Additional file 4A and B).
Discussion
Our previous microarray data showed significant up-
regulation of CDCA3 in OSCC-derived cell lines [15].
The current study also showed for the first time signifi-
cant up-regulation of CDCA3 in OSCC-derived cell lines
and primary OSCCs compared with the matched normal
counterparts. Moreover, CDCA3 protein expression in
OPLs was significantly lower than in OSCCs, whereas no
significant difference in protein expression was seen be-
tween OPLs and normal oral tissues. There was no ma-
lignant transformation of OPLs after resection. Low
expression of CDCA3 might prevent undergoing malig-
nant transformation of OPLs. In addition, CDCA3 pro-
tein expression levels in primary OSCCs were correlated
with tumor size (Table 1). These findings indicated that
overexpression of CDCA3 might be linked to human
Figure 4 Flow cytometric determination of DNA content in shCDCA3- and mock-transfected cells. A) Representative FACS analysis shows
that the number of cells in the G1 phase is significantly (*p< 0.05, Mann-Whitney’s U test) increased in shCDCA3-transfected H1 and Sa3 cells.
B) Western blot analysis of CDKIs (p21Cip1 p27Kip1, p15INK4B, and p16INK4A), CDK4, CDK6, Cyclin D1, and Cyclin E shows up-regulation of p21Cip1,
p27Kip1, p15INK4B, p16INK4A, CDK4, and Cyclin D1, and down-regulation of CDK6 and Cyclin E in the CDCA3 knockdown cells.
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OSCC development and progression.
Several cell-cycle regulator proteins are modulated by
the SCF complex. To activate the SCF complex, Cul1, a
component in the SCF complex, is conjugated with
CDCA3 [10]. However, there has been no direct evi-
dence showing that CDCA3 conjugation is required for
cell-cycle progression. To determine whether CDCA3
function is relevant to OSCC progression, we performed
the shCDCA3 experiment and found that cellular prolif-
eration decreased significantly as a result of cell-cycle ar-
rest at the G1 phase in the CDCA3 knockdown cells
with up-regulation of p21Cip1, p27Kip1, p15 INK4B, and
p16INK4A and down-regulation of CDK6 and Cyclin E.
These results were consistent with the observations thatcell-cycle progression is negatively controlled by CDKIs,
such as p21Cip1, p27Kip1, p57Kip2, and the INK4 families
(p15INK4B, p16INK4A, p18INK4C, and p19INK4D), which are
involved in cell-cycle arrest at the G1 phase and have
several functions as tumor suppressor genes [7], and that
up-regulation of p21Cip1 and/or p27Kip1 causes growth
inhibition in various cancer models [27-29]. The INK4
families can bind to CDK4 and/or to CDK6 and
inhibit the catalytic activity of the CDK/Cyclin D com-
plex [30-33]. Cyclin D1, Cyclin E, CDK4, and CDK6 are
also critical regulators of G1 progression and G1-S tran-
sition [34]. Inhibition of Cyclin D1, Cyclin E, and CDK4
activation blocks G1-S transition in the cell cycle [34-37].
Protein expression in the INK4 families (p15INK4B and
p16INK4A) was up-regulated in the CDCA3 knockdown
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lin D1 were unchanging or increased, suggesting that up-
regulation of the INK4 families might suppress the
CDK4/Cyclin D1 complex activity. Cyclin D1 is degraded
in ubiquitin-proteosome system via the SCF complex.
The reason why CDK4/CyclinD1 protein expression were
increased in the CDCA3 knockdown cells is considered
for inactivation of the SCF complex. We therefore specu-
lated that CDCA3 knockdown leads to impaired activa-
tion of the SCF complex, and consistent with that, we
found up-regulation of not only the Cip/Kip families
(p21Cip1 and p27Kip1) but also the INK4 families
(p15INK4B, p16INK4A) leading to cell-cycle arrest at the G1
phase in the CDCA3 knockdown cells.
CDCA3 is associated with Wee1 in a phosphospecific
manner, and phosphorylation of Wee1 is regulated dur-
ing the cell cycle [10]. Since Wee1 inactivates CDK1 and
Cyclin B during the S and G2 phases, its activity must
be down-regulated for mitotic progression to occur
[11,38-41]. Wee1 is a key player that serves as a mitotic
inhibitor in the intricate network of kinases and phos-
phatases that regulate the G2 switchboard [41]. The
Wee1 gene has been reported to be underexpressed in
colon cancer and non-small cell lung cancer [36,42]. In
the current study, we evaluated Wee1 mRNA expression
status in OSCC-derived cell lines. Wee1 mRNA was sig-
nificantly (Additional file 2, *p< 0.05) down-regulated in
all cell lines compared with the control. Wee1 mRNA
expression then was analyzed in shCDCA3-transfected
cells and mock-transfected cells. Wee1 expression
was significantly (Additional file 4A and B, *p< 0.05)
up-regulated in CDCA3 knockdown cells compared with
the control cells; however, CDCA3 knockdown cells stop
cell-cycle progression at the G1 phase. These data sug-
gested that G2 arrest was avoided in CDCA3 knock-
down cells through activation of cdc25, the counterpart
of Wee1, which is the switch for mitosis. Taken toge-
ther, it is noteworthy that Wee1 expression originally
decrease in the H1 and Sa3 cells used for transfection of
shCDCA3, indicating that CDCA3 plays a role not only
during the G2 phase by mediating degradation of Wee1
but also the G1 phase by mediating degradation of
CDKIs in OSCC progression.
Conclusion
Our results showed that during oral carcinogenesis over-
expression of CDCA3 occurs frequently and that it
might be closely associated with progression of OSCCs
by preventing cessation of cell-cycle progression at the
G1 phase, leading to decreased expression of CDKIs.
Further studies to identify the interaction between
CDCA3 and SCF and additional substrates for cell div-
ision cycle genes and to determine how CDCA3 is dys-
regulated in various cancers and the functional role ofCDCA3 during oral carcinogenesis might reveal novel
mechanisms for cell-cycle regulation.
Additional files
Additional file 1: mRNA and protein expression in shCDCA3-
transfected cells using qRT-PCR and Western blot analyses. A, B)
qRT-PCR shows that CDCA3 is down-regulated in shCDCA3-transfected
cells compared with the mock-transfected cells (*p < 0.05, Mann-
Whitney’s U test). Data are expressed as the means ± SEM of triplicate
results. C, D) The densitometric CDCA3 protein levels in shCDCA3- and
mock-transfected cells show that CDCA3 protein is markedly decreased
in shCDCA3-transfected cells compared with mock-transfected cells (*p < 0.05,
Mann-Whitney’s U test).
Additional file 2: Quantification of CDKIs (p21Cip1, p27Kip1, p15INK4B,
and p16INK4A), CDK4, CDK6, Cyclin D1, and Cyclin E protein
expression in shCDCA3- and mock-transfected cells. A, B) Western
blot analysis shows up-regulation of p21Cip1, p27Kip1, p15INK4B, p16INK4A,
CDK4, and Cyclin D1, and down-regulation of CDK6 and Cyclin E in the
CDCA3 knockdown cells.
Additional file 3: Quantification of Wee1 mRNA expression in
OSCC-derived cell lines by qRT-PCR analysis. Significant down-
regulation of Wee1 mRNA is seen in six OSCC-derived cell lines compared
with the HNOKs (*p < 0.05, Mann-Whitney’s U test). Data are expressed
as the means ± SEM of triplicate results.
Additional file 4: Quantification of Wee1 mRNA expression in
shCDCA3- and mock-transfected cells by qRT-PCR analysis.
Significant up-regulation of Wee1 mRNA is seen in shCDCA3-transfected
H1 (A) and Sa3 (B) cells compared with the mock-transfected cells (*p < 0.05,
Mann-Whitney’s U test). Data are expressed as the means ± SEM of triplicate
results.Abbreviations
OSCC: Oral squamous cell carcinoma; HNOKs: Human normal oral
keratinocytes; qRT-PCR: Real-time quantitative reverse transcriptase-
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